Loading
A phase 2/3 trial of F520 combined with chemotherapy in cancer of unknown primary, run by Shandong New Time Pharmaceutical Co., LTD, now recruiting.
A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP) is a phase 2/3 interventional study registered as NCT07761429 by Shandong New Time Pharmaceutical Co., LTD, with 402 participants planned, started 2026-07-08 and due to reach its primary completion in 2027-12-30. Interventions recorded: F520 combined with chemotherapy and placebo combined with chemotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shandong New Time Pharmaceutical and the tag pipeline.
Shares Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma), Cancer of unknown primary (CUP).
Shares Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma), Cancer of unknown primary (CUP).
Shares Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma), Cancer of unknown primary (CUP).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/